refined ELN 2017 by adding mutated BCOR, mutated SETBP1, and mutated IDH2 and removed NPM1mut with FLT3high in int AML; the outcome of 131 patients in the new int-risk group improved in comparison with that of the original int-risk group (n = 189) concerning both DFS (3-year rates: 32% vs. 22%) and OS (3-year rates: 41% vs. 31%) (20). This evidence concerns the gene IDH2 and acute myeloid leukemia.